May 27, 2024. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea. May 23, 2024. EISAI SHOWCASES ONCOLOGY PORTFOLIO AND ...
People also ask
Why is Eisai stock dropping?
Is Eisai a good company?
How big is Eisai Pharmaceuticals?
Who is the owner of Eisai Pharma?
Eisai's media center is where you'll find breaking news, press releases, as well as blogs and articles about the company, our people, and our innovations.
Welcome to the Eisai Official Corporate Website Latest News Page.
Search through Eisai's media center, where you'll find breaking news, blogs, and articles about the company, our people, and our innovations.
/news/index.html · May 27, 2024. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea · May 23, 2024. EISAI SHOWCASES ONCOLOGY ...
Feb 5, 2024 · Japan's Eisai aims to roll out its groundbreaking Alzheimer's drug Leqembi to 1500 people in China later this year, but expects growth to ...
Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai ...
8 days ago · Eisai's news release EISAI SHOWCASES ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2024 is posted.
Shares of pharmaceutical developers Biogen and Eisai are falling in the after-hours session. This comes following the companies received official FDA approval ...